Mentari Therapeutics (NASDAQ:MTRI) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Mentari Therapeutics (NASDAQ:MTRI) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $30.00 price objective on the stock.

Mentari Therapeutics Stock Performance

MTRI stock opened at $18.35 on Tuesday. Mentari Therapeutics has a 12 month low of $5.75 and a 12 month high of $23.30.

Insider Buying and Selling

In other Mentari Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 2,640 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were bought at an average cost of $13.10 per share, for a total transaction of $34,584.00. Following the completion of the purchase, the insider owned 98,297 shares in the company, valued at $1,287,690.70. This trade represents a 2.76% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Mentari Therapeutics Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases.